Sponsor
H. Morgan Griffith
Representative · R-VA
Representative · R-VA
The bill strengthens domestic PPE supply, quality, and transparency to boost health‑system resilience and U.S. manufacturing, but does so at the cost of higher public and provider spending, a narrowed supplier pool, potential procurement delays, and added administrative burden.
Hospitals, health systems, and frontline providers will have prioritized access to domestically sourced PPE during declared public-health emergencies, reducing the risk of shortages and improving readiness.
U.S. manufacturers and small businesses will gain more predictable federal and state contracts and phased domestic sourcing targets (50→75→100%), supporting American factory jobs and onshore production capacity.
Requiring PPE to meet CDC/OSHA quality guidance and 510(k) clearance, plus a report to inform stronger standards, should improve PPE quality and workplace safety for healthcare workers and reduce patient transmission risk.
Taxpayers, hospitals, and governments are likely to face higher costs because guaranteed purchase agreements, surge-capacity commitments, and potential new mandates raise procurement and compliance spending.
Limiting procurement to majority U.S.-owned/headquartered suppliers and prioritizing domestic-only sourcing narrows the supplier pool, which can raise prices, slow procurement, and — if U.S. capacity is insufficient during sudden surges — risk dangerous PPE shortages.
Mandating 510(k) clearance and strict quality rules may exclude some existing or novel PPE and delay approval of new products during emergencies, limiting options for providers when rapid solutions are needed.
Based on analysis of 4 sections of legislative text.
Creates an HHS program to contract with U.S. PPE manufacturers, phases in 100% domestic content by 2028, bans federally funded purchase of foreign-made PPE (with exceptions), and requires a report on PPE rule changes and clinician safety.
Official title: To direct the Secretary of Health and Human Services, in collaboration with the Assistant Secretary for Preparedness and Response and the Director of the Centers for Disease Control and Prevention, and in coordination with the Secretary of Defense and the Secretary of Homeland Security, to establish a program of entering into partnerships with eligible domestic manufacturers to ensure the availability of qualified personal protective equipment to prepare for and respond to national health or other emergencies, and for other purposes.
Introduced January 23, 2025 by H. Morgan Griffith · Last progress January 23, 2025
Creates a new HHS program to contract with eligible U.S.-based manufacturers to guarantee availability and production capacity for qualified personal protective equipment (PPE) for public health emergencies, sets phased domestic-content requirements through 2028, and requires products to meet CDC/OSHA quality guidance and FDA 510(k) clearance. It also bars federal, state, and local agencies from using federal funds to buy PPE manufactured outside the United States (with narrow, documented exceptions) and directs HHS to report to Congress on changes to federal PPE requirements and their effects on frontline clinicians during 2020–2021. The law aims to strengthen domestic PPE supply chains, prioritize U.S. manufacturers for government purchases, require documentation when foreign sourcing exceptions are claimed, and improve federal understanding of how PPE rules changed during the COVID-19 pandemic and how those changes affected workplace safety for medical staff.